The role of anti-hypertensive treatment, comorbidities and early introduction of LMWH in the setting of COVID-19: A retrospective, observational study in Northern Italy.

Results confirmed that the use of ACE-I was a significant protective factor for COVID-19 in-hospital mortality (Hazard Ratio: 0.61; 95% CI: 0.38–0.98; p = 0.04) with a highly significant model ( p = 9.99E-22; n = 444) ( Table 3 ). 4.

also in 132,142 other papers

We found that ACE—I, which acts by inhibiting the conversion from angiotensin I to angiotensin II, showed a trend in protecting from mortality from COVID-19 and was significant in delaying mortality as shown by multivariate Cox regression analysis unlike ARBs, which antagonize the effects of angiotensin II on its receptors [ 2 , 3 ].

also in 53,322 other papers